Clinical potential of cariprazine in the treatment of acute mania

Basit Öğe Kaydı
dc.contributor.authorAltınbaş, Kürşat
dc.contributor.authorGülöksüz, Sinan
dc.contributor.authorOral, E. Timuçin
dc.date.accessioned2020-11-21T15:53:27Z
dc.date.available2020-11-21T15:53:27Z
dc.date.issued2013en_US
dc.departmentİstanbul Ticaret Üniversitesien_US
dc.descriptionPubMed ID: 24048386en_US
dc.description.abstractCariprazine (RGH-188, trans-4-{2-[4-(2,3-dichlorophenyl)-piperazine-1-yl]- ethyl}-N,N-dimethylcarbamoyl-cyclohexyl-Amine hydrochloride), is a novel antipsychotic with dopamine D2 and D3 receptors antagonist-partial agonist properties. Cariprazine has also moderate affinity for serotonin 5-hydroxytryptophan (5-HT) 1A receptors, high affinity for 5-HT1B receptors with pure antagonism and low affinity for 5-HT2A receptors. Randomized, double blind, placebo controlled, flexible-dose (3-12 mg/day) studies have demonstrated cariprazine is effective in both schizophrenia and acute manic episodes associated with bipolar disorder. The incidence of serious adverse events in cariprazine arm was no different than in placebo arm in these studies. The most common adverse events were extrapyramidal symptoms, headache, akathisia, constipation, nausea, and dyspepsia which can be explained with cariprazine's partial dopamine agonism. Although cariprazine treatment was associated with a higher incidence of treatmentemergent adverse events, particularly akathisia and tremor, common side effects of marketed second generation antipsychotics such as weight gain, metabolic disturbances, prolactin increase or QTc prolongation were not associated with cariprazine, probably due to its moderate to low binding affinity for histamine H1 and 5-HT2C receptors. Animal studies show that cariprazine may have additional therapeutic benefit on impaired cognitive functioning with D3 receptor activity, however clinical data is still scarce. The aim of this article is to review the potential use of cariprazine for the treatment of acute manic episodes in the light of the preclinical and clinical trials reported to date. © Medicinska naklada - Zagreb, Croatia.en_US
dc.identifier.endpage213en_US
dc.identifier.issn0353-5053
dc.identifier.issue3en_US
dc.identifier.pmid24048386en_US
dc.identifier.scopus2-s2.0-84885234331en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage207en_US
dc.identifier.urihttps://hdl.handle.net/11467/3590
dc.identifier.volume25en_US
dc.identifier.wosWOS:000338630000002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.relation.ispartofPsychiatria Danubinaen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAntipsychoticen_US
dc.subjectBipolar disorderen_US
dc.subjectCariprazineen_US
dc.subjectManiaen_US
dc.subjectPsychopharmacologyen_US
dc.titleClinical potential of cariprazine in the treatment of acute maniaen_US
dc.typeReviewen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu